Phibro Animal Health Corp

In the past week, we also increased the size of our revolving credit facility by $125 million through an oversubscribed process, further strengthening our liquidity and financial flexibility.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

Interest expense, net Interest expense, net of $10.4 million for the three months ended March 31, 2026 increased $1.1 million, as compared to the three months ended March 31, 2025, due to the expiration of a favorable interest rate swap agreement on $300.0 million of notional debt principal, partially offset by lower interest rates and higher patronage income received from the lenders providing the Term A-2 Loan.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

BALANCE SHEET AND CASH FLOWS Free cash flow was $12.8 million for the twelve months ended March 31, 2026 (Free cash flow equals cash flow from operating activities less capital expenditures).

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

3.1x gross leverage ratio as of March 31, 2026 - $740.9 million total debt - $240.7 million Adjusted EBITDA for the twelve months ended March 31, 2026 - Cash and short-term investments of $77.5 million as of March 31, 2026 On April 28, 2026, our credit agreement was amended to increase the borrowing capacity of our revolving credit facility by $125 million, from $310 million to an aggregate commitment of $435 million.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

The expanded borrowing capacity provides the Company with enhanced operating flexibility.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

DISCLOSURE NOTICES Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

SG&A for the three months ended March 31, 2026 included $3.4 million of costs associated with Phibro Forward income growth initiatives, $0.6 million for intangible asset amortization, $0.1 million for acquisition-related costs, and $0.2 million of stock-based compensation expense related to awards granted to certain named executive officers in fiscal year 2024.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

SG&A for the three months ended March 31, 2025 included $4.0 million of costs associated with Phibro Forward income growth initiatives, $0.6 million for acquisition-related costs, $0.6 million for intangible asset amortization, and $0.2 million of stock-based compensation expense, partially offset by $1.5 million related to an insurance settlement gain.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

The effective income tax rate in the prior year included (i) various exchange rate gains, (ii) changes in uncertain tax positions related to prior years and (iii) certain non-deductible write-offs in connection with the closure of an immaterial business included as part of the Phibro Forward initiatives.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

* Calculation not meaningful (1) Reflects ratio to total net sales 8 (2) Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

For the three and nine months ended March 31, 2026, this includes $3.4 million and $7.0 million, respectively, recorded within selling, general, and administrative expenses primarily for consultancy costs related to the initiative.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

Net income of $92 million to $100 million, 99% growth Diluted EPS of $2.25 to $2.44, 97% growth Adjusted EBITDA of $247 million to $255 million, 37% growth Adjusted net income of $122 million to $127 million, 47% growth Adjusted diluted EPS of $2.98 to $3.10, 45% growth Adjusted effective tax rate of ~25% Guidance for GAAP measures assumes no additional foreign exchange (gains) losses for the year ending June 30, 2026 and no recovery of tariffs previously imposed under the International Emergency Economic Powers Act.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

DISCLOSURE NOTICES Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

If one or more of these risks or uncertainties materialize, or if management s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned Forward-Looking 5 Statements and Risk Factors.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort.

SEC original ↗Phibro Animal Health Corp — Earnings release (8-K exhibit)EX-99May 6, 2026

Legal Proceedings 45 Item 1A.

SEC original ↗Phibro Animal Health Corp — 10-Q Quarterly report10-QMay 6, 2026